Remi Barbier, the chairman and chief executive, and Lindsay Burns, the chief scientist at Cassava Sciences, have resigned amidst controversy over an Alzheimer's drug named simufilam.
Top officials' resignations follow the charge of fraud against neuroscientist Dr. Hoau-Yan Wang for alleged data falsification in studies supporting Cassava's drug candidate, simufilam.
Wang and Burns collaborated on studies, with more than five of Wang's papers being retracted or questioned. City University of New York committee faulted Dr. Burns for errors in the research.
SEC is investigating Cassava Sciences, adding to criticisms by scientists about methodological oddities and suspicious figures in papers on simufilam. Rutgers University's Dr. William Hu hopes for more transparency in Cassava's research.
#alzheimers-drug-controversy #data-falsification #scientific-research-ethics #pharmaceutical-industry #sec-investigation
Collection
[
|
...
]